NCT06562309Completed
Fecal Microbiota and Monocyte Trained Immunity in CHD Patients With Different hsCRP
Fecal Microbiota and Monocyte Trained Immunity in Patients With Coronary Heart Disease and Different Level of High-sensitivity C-reactive Protein (hsCRP)
Source: ClinicalTrials.gov · Last updated 20 Aug 2024
Brief summary (registry, in English)
This single-center study enrolled patients aged 35-75 years who were diagnosed with unstable angina (UA), and had at least one of the three major coronary arteries with a ≥ 50% reduction in lumen diameter by angiographic visual estimation. Patients were all recruited at the Department of Cardiology, Union Hospital, Wuhan, Hubei Province, China. Feces and blood samples were collected on admission were used promptly for ex vivo studies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 14 Aug 2024
- Start date
- 11 May 2021
- Primary completion date
- 30 Apr 2024
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Coronary artery disease
- NCT number
- NCT06562309
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 11 May 2021 to the primary completion date, 30 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior myocardial infarction
- Ongoing acute, chronic, or concurrent infectious disease
- Surgery 3 months before sample collection
- Immunization with a vaccine within 4 weeks before sample collection
Other illness
- Have a history of malignancies, auto-immune, auto-inflammatory disease or on immunomodulatory medication
- History of primary or secondary immunodeficiency
- History of chronic obstructive pulmonary disease (COPD)
Lab values
- Left ventricular ejection fraction ≤ 40% on echocardiography
- Renal failure with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2
- Active liver disease with alanine aminotransferase (ALT \>80 U/L) or aspartate aminotransferase (AST \> 80 U/L)
Other
- Pregnancy, or breast feeding
- Refuse to provide written consent
- Any other circumstances in which the investigator judges that the patient is not suitable
Who the study is looking for
- Age \>35 and \<75 years
- Admitted for UA and had at least one of the three major coronary arteries with ≥50% reduction in lumen diameter by angiographic visual estimation
- Informed consent obtained
Age in the registry: 35 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.